Pd-L1 Testing Based on The SP142 Antibody in Metastatic Triple-Negative Breast Cancer: Summary of an Expert Round-Table Discussion

References

• Yu LY , TangJ, ZhangCMet al. New immunotherapy strategies in breast cancer. Int. J. Environ. Res. Public Health14(1), 68 (2017).
   PubMed Web of Science ®Google Scholar
• Cimino-Mathews A , FooteJB, EmensLA. Immune targeting in breast cancer. Oncology (Williston Park)29(5), 375–385 (2015).
   PubMed Web of Science ®Google Scholar
• Bertucci F , GoncalvesA. Immunotherapy in breast cancer: the emerging role of PD-1 and PD-L1. Curr. Oncol. Rep.19(10), 64 (2017).
   PubMed Web of Science ®Google Scholar
• Cao Y , AxupJY, MaJSet al. Multiformat T-cell-engaging bispecific antibodies targeting human breast cancers. Angew. Chem. Int. Ed. Engl.54(24), 7022–7027 (2015).
   PubMed Web of Science ®Google Scholar
• Berry DA , CirrincioneC, HendersonICet al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA295(14), 1658–1667 (2006).
   PubMed Web of Science ®Google Scholar
• Den Brok WD , SpeersCH, GondaraL, BaxterE, TyldesleySK, LohrischCA. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed. Breast Cancer Res. Treat.161(3), 549–556 (2017).
   PubMed Web of Science ®Google Scholar
• Bonotto M , GerratanaL, PolettoEet al. Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist19(6), 608–615 (2014).
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) . Breast cancer version 4.2020. (2020). https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
   Google Scholar
• Cardoso F , SenkusE, CostaAet al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann. Oncol.29(8), 1634–1657 (2018).
   PubMed Web of Science ®Google Scholar
• Ruffell B , AuA, RugoHS, EssermanLJ, HwangES, CoussensLM. Leukocyte composition of human breast cancer. Proc. Natl Acad. Sci. USA109(8), 2796–2801 (2012).
   PubMed Web of Science ®Google Scholar
• Liu S , LachapelleJ, LeungS, GaoD, FoulkesWD, NielsenTO. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res.14(2), R48 (2012).
   PubMed Web of Science ®Google Scholar
• Mittendorf EA , PhilipsAV, Meric-BernstamFet al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol. Res.2(4), 361–370 (2014).
   PubMed Web of Science ®Google Scholar
• Katz H , AlsharediM. Immunotherapy in triple-negative breast cancer. Med. Oncol.35(1), 13 (2017).
   PubMed Web of Science ®Google Scholar
• Emens LA , CruzC, EderJPet al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a Phase I study. JAMA Oncol.5(1), 74–82 (2019).
   PubMed Web of Science ®Google Scholar
• Emens LA , AdamsS, BarriosCHet al. LBA16 IMpassion130: final OS analysis from the pivotal Phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer. Ann. Oncol.31(Suppl. 4), S1148 (2020).
   PubMedGoogle Scholar
• Nanda R , ChowLQ, DeesECet al. Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 study. J. Clin. Oncol.34(21), 2460–2467 (2016).
   PubMed Web of Science ®Google Scholar
• Cortes J , CesconDW, RugoHSet al. KEYNOTE-355: randomized, double-blind, Phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. J. Clin. Oncol.38(Suppl. 15), Abstract 1000 (2020).
   Google Scholar
• Ratcliffe MJ , SharpeA, MidhaAet al. Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small-cell lung cancer. Clin. Cancer Res.23(14), 3585–3591 (2017).
   PubMed Web of Science ®Google Scholar
• Schats KA , van VreEA, BoeckxCet al. Optimal evaluation of programmed death ligand-1 on tumor cells versus immune cells requires different detection methods. Arch. Pathol. Lab. Med.142(8), 982–991 (2018).
   PubMed Web of Science ®Google Scholar
• Karnik T , KimlerBF, FanF, TawfikO. PD-L1 in breast cancer: comparative analysis of 3 different antibodies. Hum. Pathol.72, 28–34 (2018).
   PubMed Web of Science ®Google Scholar
• Kintsler S , CassataroMA, DroschM, HolenyaP, KnuechelR, BraunschweigT. Expression of programmed death ligand (PD-L1) in different tumors. Comparison of several current available antibody clones and antibody profiling. Ann. Diagn. Pathol.41, 24–37 (2019).
   PubMed Web of Science ®Google Scholar
• Noske A , AmmanJ, WagnerDCet al. Reproducibility and concordance of 4 clinically developed programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays in triple negative breast cancer (TNBC). Ann. Oncol.30(Suppl. 5), v130–131 ( Abstract 359P) (2019).
   Google Scholar
• Ionescu DN , DownesMR, ChristofidesA, TsaoMS. Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective. Curr. Oncol.25(3), e209–e216 (2018).
   PubMed Web of Science ®Google Scholar
• Lantuejoul S , Sound-TsaoM, CooperWAet al. PD-L1 testing for lung cancer in 2019: perspective from the IASLC Pathology Committee. J. Thorac. Oncol.15(4), 499–519 (2020).
   PubMed Web of Science ®Google Scholar
• Parra ER , VillalobosP, MinoB, Rodriguez-CanalesJ. Comparison of different antibody clones for immunohistochemistry detection of programmed cell death ligand 1 (PD-L1) on non-small cell lung carcinoma. Appl. Immunohistochem. Mol. Morphol.26(2), 83–93 (2018).
   PubMedGoogle Scholar
• US FDA . FDA approves atezolizumab for first-line treatment of metastatic NSCLC with high PD-L1 expression (2020). https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-first-line-treatment-metastatic-nsclc-high-pd-l1-expression
   Google Scholar
• US FDA . List of cleared or approved companion diagnostic devices (in vitro and imaging tools) (2020). https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools
   Google Scholar
• US FDA . FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer (2020). https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-atezolizumab-pd-l1-positive-unresectable-locally-advanced-or-metastatic-triple-negative
   Google Scholar
• Schmid P , AdamsS, RugoHSet al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med.379(22), 2108–2121 (2018).
   PubMed Web of Science ®Google Scholar
• Schmid P , RugoHS, AdamsSet al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet Oncol.21(1), 44–59 (2020).
   PubMed Web of Science ®Google Scholar
• Hirsch FR , McelhinnyA, StanforthDet al. PD-L1 immunohistochemistry assays for lung cancer: results from Phase 1 of the blueprint PD-L1 IHC assay comparison project. J. Thorac. Oncol.12(2), 208–222 (2017).
   PubMed Web of Science ®Google Scholar
• Rugo HS , LoiS, AdamsSet al. Performance of PD-L1 immunohistochemistry assays in unresectable locally advanced or metastatic triple-negative breast cancer: post hoc analysis of IMpassion130. Ann. Oncol.30(Suppl. 5), v858–959 ( Abstract LBA820) (2019).
   PubMedGoogle Scholar
• US FDA . Data sheet for VENTANA PD-L1 (SP142) Assay (2020). https://www.accessdata.fda.gov/cdrh_docs/pdf16/p160002s009c.pdf
   Google Scholar
• Dennis E , KockxMM, HarlowG, CaiZ, BloomK, ElgabryE. Effective and globally reproducible digital pathologist training program on PD-L1 immunohistochemistry scoring on immune cells as a predictive biomarker for cancer immunotherapy in triple negative breast cancer. Cancer Res.80(Suppl. 4), ( Abstract PD5-02) (2020).
   PubMed Web of Science ®Google Scholar
• Reisenbichler ES , HanG, BellizziAet al. Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer. Mod. Pathol.33, 1746–1752 (2020).
   PubMed Web of Science ®Google Scholar
• Plasilova ML , HayseB, KilleleaBK, HorowitzNR, ChagparAB, LanninDR. Features of triple-negative breast cancer: analysis of 38,813 cases from the national cancer database. Medicine (Baltimore)95(35), e4614 (2016).
   PubMed Web of Science ®Google Scholar
• Li Y , VennapusaB, ChangCWet al. Prevalence study of PD-L1 SP142 assay in metastatic triple-negative breast cancer. Appl. Immunohistochem. Mol.Morphol.doi:10.1097/PAI.0000000000000857 (2020) ( Epub ahead of print).
   Google Scholar
• Exman P , Garrido-CastroA, TolaneyS. PD-L1 testing in patients with breast cancer: controversies and current practice. Curr. Breast Cancer Rep.11, 353–357 (2019).
   Web of Science ®Google Scholar
• Pelekanou V , BarlowWE, NahlehZAet al. Tumor-infiltrating lymphocytes and PD-L1 expression in pre- and posttreatment breast cancers in the SWOG S0800 Phase II neoadjuvant chemotherapy trial. Mol. Cancer Ther.17(6), 1324–1331 (2018).
   PubMed Web of Science ®Google Scholar
• Li X , WarrenS, PelekanouVet al. Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial. J. Immunother. Cancer7(1), 88 (2019).
   PubMedGoogle Scholar
• Dieci MV , TsvetkovaV, GriguoloGet al. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I–III patients treated with standard therapy. Eur. J. Cancer136, 7–15 (2020).
   PubMed Web of Science ®Google Scholar
• Yuan C , LiuZ, YuQet al. Expression of PD-1/PD-L1 in primary breast tumours and metastatic axillary lymph nodes and its correlation with clinicopathological parameters. Sci. Rep.9(1), 14356 (2019).
   PubMedGoogle Scholar
• Schrijver WA , vander Groep P, HoefnagelLDet al. Influence of decalcification procedures on immunohistochemistry and molecular pathology in breast cancer. Mod. Pathol.29(12), 1460–1470 (2016).
   PubMed Web of Science ®Google Scholar
• Li Y , ChangCW, TranD, DenkerM, HedgeP, MolineroL. Prevalence of PDL1 and tumor infiltrating lymphocytes (TILs) in primary and metastatic TNBC. Cancer Res.78(Suppl. 4), ( Abstract PD6-01) (2018).
   Web of Science ®Google Scholar
• FDA summary of safety and effectiveness data for VENTANA PD-L1 (SP142) assay (2020). https://www.accessdata.fda.gov/cdrh_docs/pdf16/p160002s009b.pdf
   Google Scholar
• Garrido P , CondeE, DeCastro Jet al. Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin. Transl. Oncol.22(7), 989–1003 (2020).
   PubMed Web of Science ®Google Scholar
• International Association for the Study of Lung Cancer. Soo RA, Asuncion BR, Buettner R. PD-L1 SP142 assay . IASLC Atlas of PD-L1 Immunohistochemistry Testing in Lung Cancer. TsaoMS, KerrKM, DacicS, YatabeY, HirschFR (Eds). Rx Press, CO, USA, 63–72 (2017).
   Google Scholar